ADARx prices $446 million IPO as RNAi biotech

ADARx Pharmaceuticals priced its upsized initial public offering at $446.3 million on September 24, 2026, selling over 26 million shares at $17 each. The debut marks the first traditional U.S. IPO for an RNAi biotech in over a decade. Backed by an additional $89 million private placement and a prior $335 million development deal with AbbVie, ADARx plans to advance its pipeline, including its late-stage hereditary angioedema candidate onvuzosiran, beyond traditional liver targets.

ADARx IPO pricing and debut

• ▪ADARx Pharmaceuticals scheduled its trading debut on the Nasdaq under the ticker symbol ADRX for Friday, September 25, 2026
• ▪ADARx Pharmaceuticals priced its initial public offering at $446.3 million on Thursday, September 24, 2026, selling over 26 million shares at $17 per share

RNA interference pipeline strategy

• ▪While all currently marketed RNA interference medicines target the liver, ADARx Pharmaceuticals is developing a pipeline of therapies directed at targets both inside and outside the liver
• ▪ADARx Pharmaceuticals is conducting multiple mid-stage trials for agazisiran, targeting certain kidney diseases, geographic atrophy, and the rare blood disorder paroxysmal nocturnal hemoglobinuria
• ▪ADARx Pharmaceuticals' pipeline includes a stroke prevention treatment and two prospects for obesity and neurological disorders that act on targets outside of the liver
• ▪In its initial public offering filing, ADARx Pharmaceuticals stated that RNA interference technology has been constrained by delivery and potency challenges that have blunted the technology's broader potential

Development of lead candidate onvuzosiran

• ▪Early-stage study results showed that onvuzosiran could reduce levels of the protein plasma kallikrein by up to 93%, with early Phase 3 data expected by the end of 2027, ADARx said
• ▪ADARx Pharmaceuticals claimed that onvuzosiran could be more potent than Ionis Pharmaceuticals' existing RNA-based treatment for hereditary angioedema and could be dosed as infrequently as twice yearly
• ▪ADARx Pharmaceuticals' most advanced drug candidate, onvuzosiran, is in late-stage testing for patients with the rare swelling disorder hereditary angioedema

AbbVie partnership and investments

• ▪In 2025, AbbVie paid ADARx Pharmaceuticals $335 million up front in a deal to codevelop drugs for neurological conditions, immune disorders, and cancer
• ▪ADARx Pharmaceuticals secured about $89 million through a private stock sale to its development partner AbbVie in connection with its initial public offering

Biotechnology IPO market trends

• ▪BioPharma Dive data showed that the bulk of the 22 drug companies to price initial public offerings in 2026 have been small molecule or biologics developers
• ▪Four biotechnology firms filed plans to go public in the week leading up to September 24, 2026, including City Therapeutics, Iambic Therapeutics, and TRex Bio
• ▪ADARx Pharmaceuticals' initial public offering is the first for an RNA-focused biotech in almost two years and the first traditional initial public offering for an RNAi biotech in the United States in over a decade
• ▪While biotech firms have dominated recent initial public offering activity in 2026, Renaissance Capital warned that rising bond yields, rate hikes, and artificial intelligence spending concerns could slow future offerings

Debatable claims

• ▪RNA interference therapeutics can successfully target diseases outside the liver
• ▪Public markets are the appropriate venue to fund high-risk biotech platforms